Advertisement

FDA Approves New Omega-3 Supplement — Physician’s First Watch

Medical News |
May 7, 2014

FDA Approves New Omega-3 Supplement

By Larry Husten

The FDA has approved a new omega-3 supplement (brand name, Epanova) to treat adults with severe hypertriglyceridemia, defined as triglyceride levels 500 mg/dL or higher.

In its announcement, the manufacturer said that Epanova is the first omega-3 formulation approved by the FDA in free fatty acid form. It will be available in 1-g capsules and has been approved for 2-g and 4-g dosages, which can be taken with or without food.

There are currently two other prescription formulations of omega-3 supplements on the market: Lovaza and Vascepa. All three are approved only for the treatment of severe hypertriglyceridemia, though studies of expanded indications are underway.

Reader Comments (2)

M.S. Other Healthcare Professional, Other, Retd. Res. Scientist & chair/HIV/AiIDS Conf Cmte/NYC Health Dept.

In a case of 'brittle Hypo-glycemia' (25mg% at 3 1/2 hrs. into glucose tolerance test).) would a result of moderate to high triglceride levesl be expected in a fasting specimen??

DAVID KELLER Physician, Internal Medicine, disabled

The 2012 Endocrine Society recommendations raised the threshold definition of severe elevation of triglycerides, requiring pharmacological treatment to reduce the risk of pancreatitis, to greater than or equal to 1000 mg/dL (1). The older threshold of 500 mg/dL was determined to present a much lower risk of pancreatitis than had been previously thought.

1. Berglund L, Brunzell J, Goldberg A, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2969-2989.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement